In contrast, studies by Tarantino et al. [14] and Ilie et al. [19] found no statistically significant differences in pCR rates between non-metastatic HER2-low and HER2 0 BC, irrespective of HR status. The gene discussed is ERBB2; the disease is breast cancer.